uniQure issued new patents covering methods of treating coagulopathies.
uniQure announced that the U.S. Patent and Trademark Office has granted Patent Number 9,982,248 which broadly covers methods of treating coagulopathies, or bleeding disorders, including hemophilia B, using AAV gene therapy with nucleic acid encoding the hyperactive Factor IX, or FIX, Padua variant. This is the second U.S. patent to issue, along with the previously issued U.S. Patent Number 9,249,405, in a patent family that uniQure acquired from the inventor, Professor Paolo Simioni, a renowned hemophilia expert at the University of Padua, Italy. In addition to the U.S. patent, on February 20, 2018 the Canadian Intellectual Property Office granted Patent Number 2,737,094, which broadly covers FIX-Padua nucleic acids for use in gene therapy and FIX-Padua polypeptides for use in FIX replacement therapy. uniQure also is currently pursuing European patents directed toward therapeutic uses of FIX-Padua nucleic acids and polypeptides. uniQure also announced today the issuance of a new patent further strengthening the company's intellectual property related to its proprietary insect cell-based AAV manufacturing process. U.S. Patent Number 9,840,694 includes claims covering nanofiltration to selectively remove potential residual baculovirus from the product. The Company believes this nanofiltration step is important for product quality and safety and that nanofiltration generally may be required to comply with viral clearance standards established by global regulatory authorities. Related patents were previously granted in Europe, Japan and several other jurisdictions.
|Printer friendly Cite/link Email Feedback|
|Date:||May 29, 2018|
|Previous Article:||Microbot Medical announces successful completion of pre-clinical study.|
|Next Article:||First fire reports 'mixed bag' for PG&E, says Deutsche Bank.|